Breaking News Instant updates and real-time market news.

NVS

Novartis

$78.29

-0.16 (-0.20%)

15:02
10/09/16
10/09
15:02
10/09/16
15:02

Novartis reports Phase 3 data on Tafinlar-Mekinist in melanoma

Novartis announced data from the Phase III COMBI-v study demonstrating an overall survival and a progression-free survival benefit for patients with BRAF V600 mutation-positive advanced melanoma when treated first-line with the combination of Tafinlar and Mekinist compared to vemurafenib monotherapy. The results of the study, which was conducted in 704 patients, are being presented at the European Society for Medical Oncology 2016 Congress. Results from the COMBI-v study found the estimated three-year survival rate to be 45% of patients receiving the combination of Tafinlar + Mekinist compared with 31% of patients who received vemurafenib monotherapy. There were 34 patients who crossed over from the vemurafenib monotherapy arm to the combination arm after the combination demonstrated a significant OS benefit in a prior analysis. Additionally, the estimated three-year progression-free survival rate was 24% for the combination arm and 10%m for the vemurafenib monotherapy arm. At three years of follow up, the combination of Tafinlar + Mekinist continued to demonstrate a benefit on the measures of duration of response and overall response rate, in line with results seen at the two-year follow up analysis. The safety results were consistent with the profile observed to date for the combination and consistent with the profile observed for vemurafenib monotherapy; no new safety concerns were observed.

NVS Novartis
$78.29

-0.16 (-0.20%)

08/31/16
LEER
08/31/16
NO CHANGE
Target $61
LEER
Outperform
Teva price target lowered to $61 from $66 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva (TEVA) to $61 from $66 on loss of Copaxone patent challenge as an upside catalyst. The analyst believes Teva's share price implies a generic entrant sometime in the second half of 2017 after losing an Inter Partes Review decision on two Copaxone 40mg anchor patents. In order to mitigate EPS downside in 2017-2018 and eliminate business uncertainty, Gerberry thinks the company should settle its Copaxone patent dispute with Novartis (NVS) and Momenta (MNTA), which he sees as "the most credible" generic threat. The analyst reiterates an Outperform rating on Teva's shares.
08/31/16
PIPR
08/31/16
NO CHANGE
PIPR
Piper's Schimmer unsure of impact from Novartis CAR-T shakeup
Piper Jaffray analyst Joshua Schimmer said he's struggling with the implications of the news that Novartis (NVS) is reportedly eliminating its Cell and Gene Therapy unit as a stand-alone entity, which is primarily focused on development of CAR-T and adoptive immunotherapies. On the one hand, removing a leading competitor is a positive for the rest of the field, Schimmer tells investors in a research note. On the other hand, the move by Novartis could signal "significant challenges" in the field, the analyst adds. Schimmer continues to prefer companies "with unique and differentiated approaches," namely Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), Amgen (AMGN), Celgene (CELG) and bluebird bio (BLUE). Juno Therapeutics (JUNO) and Kite Pharma (KITE) are down 6% and 5%, respectively, in midday trading.
09/02/16
LEER
09/02/16
NO CHANGE
LEER
Outperform
Teva third Copaxone patent invalidated as expected, says Leerink
Leerink analyst Jason Gerberry says Teva (TEVA) suffered a largely expected loss in its Copaxone 40mg patent battle, with the Patent Trial and Appeal Board, or PTAB, ruling a third patent invalid. The analyst believes the company will likely appeal the loss, along with PTAB rulings rendered last week that other Copaxone patents were invalid. Gerberry sees the bull case scenario of Teva securing patent exclusivity of the Copaxone 40mg as unlikely and says a settlement with Momenta (MNTA) and Novartis (NVS) is the most logical course of action to mitigate 2017-2018E EPS risk. He reiterates an Outperform rating on Teva's shares.
09/20/16
CHDN
09/20/16
INITIATION
Target $95
CHDN
Buy
Novartis initiated with a Buy at Chardan
Chardan initiated Novartis with a Buy and a $95 price target.

TODAY'S FREE FLY STORIES

PVTB

PrivateBancorp

$48.78

2 (4.28%)

, CM

CIBC

$81.64

0.26 (0.32%)

14:41
12/02/16
12/02
14:41
12/02/16
14:41
Hot Stocks
Alpine Associates opposes PrivateBancorp's acquisition by CIBC »

Alpine Associates…

PVTB

PrivateBancorp

$48.78

2 (4.28%)

CM

CIBC

$81.64

0.26 (0.32%)

KRE

SPDR S&P Regional Banking ETF

$53.05

-0.415 (-0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMX

BioPharmX

$0.38

0.0729 (23.52%)

14:38
12/02/16
12/02
14:38
12/02/16
14:38
Hot Stocks
Breaking Hot Stocks news story on BioPharmX »

Vivo Capital VIII reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$118.87

0.36 (0.30%)

14:37
12/02/16
12/02
14:37
12/02/16
14:37
Hot Stocks
Celgene agrees to complete acquisition of Acetylon »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 04

    Dec

  • 06

    Dec

KVHI

KVH Industries

$10.85

-0.05 (-0.46%)

14:35
12/02/16
12/02
14:35
12/02/16
14:35
Hot Stocks
KVH Industries names Donald Reilly CFO »

KVH Industries announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWPH

GW Pharmaceuticals

$109.28

-2.37 (-2.12%)

14:35
12/02/16
12/02
14:35
12/02/16
14:35
Options
GW Pharmaceuticals put volume heavy and directionally bearish »

Bearish flow noted in GW…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 05

    Dec

IWM

iShares Trust Russell 2000 Index Fund

$130.69

-0.28 (-0.21%)

, RUT

Russell 2000 Index

14:23
12/02/16
12/02
14:23
12/02/16
14:23
Technical Analysis
On The Fly: Weekly technical notes for the Russell 2000 »

The index at time of…

IWM

iShares Trust Russell 2000 Index Fund

$130.69

-0.28 (-0.21%)

RUT

Russell 2000 Index

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MHK

Mohawk

$189.72

-1.76 (-0.92%)

14:21
12/02/16
12/02
14:21
12/02/16
14:21
Recommendations
Mohawk analyst commentary  »

Mohawk a buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
12/02/16
12/02
14:16
12/02/16
14:16
Technical Analysis
NYSE market internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:16
12/02/16
12/02
14:16
12/02/16
14:16
Technical Analysis
NASDAQ market internals summary »

Volume is heavier than…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$13.20

0.32 (2.48%)

14:15
12/02/16
12/02
14:15
12/02/16
14:15
Options
Sears put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

14:15
12/02/16
12/02
14:15
12/02/16
14:15
General news
Fedspeak will be compressed next week »

Fedspeak will be…

EDU

New Oriental Education

$47.96

-1.03 (-2.10%)

14:08
12/02/16
12/02
14:08
12/02/16
14:08
Periodicals
New Oriental Education engaged in college application fraud, Reuters says »

Former and current…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$219.50

-0.07 (-0.03%)

, SPX

S&P 500

$2,190.69

-0.39 (-0.02%)

14:07
12/02/16
12/02
14:07
12/02/16
14:07
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

The S&P 500 (SPX)…

SPY

SPDR S&P 500 ETF Trust

$219.50

-0.07 (-0.03%)

SPX

S&P 500

$2,190.69

-0.39 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:05
12/02/16
12/02
14:05
12/02/16
14:05
General news
Oil rallies while equities stall »

Stocks have stalled out,…

TITN

Titan Machinery

14:02
12/02/16
12/02
14:02
12/02/16
14:02
Downgrade
Titan Machinery rating change  »

Titan Machinery…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SON

Sonoco Products

$52.74

-1.035 (-1.92%)

, BRK.A

Berkshire Hathaway

$238,530.00

-1291 (-0.54%)

14:01
12/02/16
12/02
14:01
12/02/16
14:01
Hot Stocks
Sonoco to invest $20M in new Atlanta packaging center to support Duracell ops »

Sonoco (SON) announced it…

SON

Sonoco Products

$52.74

-1.035 (-1.92%)

BRK.A

Berkshire Hathaway

$238,530.00

-1291 (-0.54%)

BRK.B

Berkshire Hathaway

$159.07

-1.05 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 02

    Dec

EDU

New Oriental Education

$48.06

-0.93 (-1.90%)

14:00
12/02/16
12/02
14:00
12/02/16
14:00
Hot Stocks
Breaking Hot Stocks news story on New Oriental Education »

New Oriental down over 5%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EDU

New Oriental Education

$48.06

-0.93 (-1.90%)

14:00
12/02/16
12/02
14:00
12/02/16
14:00
Periodicals
Breaking Periodicals news story on New Oriental Education »

Standards council to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYCC

ClubCorp

$13.40

0.2 (1.52%)

14:00
12/02/16
12/02
14:00
12/02/16
14:00
Options
Call buyer opens the largest open interest block in ClubCorp options »

Call buyer opens the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:00
12/02/16
12/02
14:00
12/02/16
14:00
General news
NY Fed accepted $167.88 B in daily reverse repos »

NY Fed accepted $167.88 B…

SBUX

Starbucks

$58.51

0.54 (0.93%)

13:51
12/02/16
12/02
13:51
12/02/16
13:51
Hot Stocks
Starbucks in 'capable hands' after 'surprising' CEO change, analysts say »

Shares of Starbucks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

TOT

Total

$47.82

0.07 (0.15%)

, RDS.A

Royal Dutch Shell

$52.01

0.225 (0.43%)

13:50
12/02/16
12/02
13:50
12/02/16
13:50
Periodicals
Obama expected to sign bill extending Iran sanctions, Reuters reports »

White House says…

TOT

Total

$47.82

0.07 (0.15%)

RDS.A

Royal Dutch Shell

$52.01

0.225 (0.43%)

BP

BP

$35.56

0.17 (0.48%)

XOM

Exxon Mobil

$87.36

0.12 (0.14%)

CVX

Chevron

$113.34

0.05 (0.04%)

COP

ConocoPhillips

$48.17

-0.05 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 05

    Dec

  • 13

    Dec

SDRL

Seadrill

$2.93

-0.15 (-4.87%)

13:50
12/02/16
12/02
13:50
12/02/16
13:50
Options
Far downside puts opened in Seadrill »

Far downside puts opened…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:50
12/02/16
12/02
13:50
12/02/16
13:50
General news
Action Economics Survey results: »

Action Economics Survey…

13:43
12/02/16
12/02
13:43
12/02/16
13:43
Conference/Events
JPMorgan aerospace & defense analyst holds an analyst/industry conference call »

Aerospace & Defense…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.